$NKTR

Class action filed against Nektar Therapeutics alleging false trial statements regarding REZOLVE-AA enrollment. Lead plaintiff deadline: May 5, 2026.

Nektar Therapeutics ($NKTR) faces securities fraud lawsuit after Phase 2b alopecia trial failed due to enrollment violations, triggering 7.8% stock decline.

Pomerantz LLP sues Nektar Therapeutics for alleged securities fraud over failed clinical trial enrollment; stock falls 7.77%.

Rosen Law Firm initiates securities class action against $NKTR for alleged false statements regarding enrollment protocols in REZOLVE-AA trial. Lead plaintiff deadline: May 5, 2026.

Law firm announces lead plaintiff deadlines for shareholder class actions against $AQST, $NKTR, and $EOSE over alleged false statements and misleading guidance.

Class action lawsuit alleges Nektar Therapeutics misled investors about REZOLVE-AA trial enrollment standards, claiming executives made false statements about trial integrity.

Nektar Therapeutics faces class action lawsuit alleging securities fraud over alleged REZOLVE-AA trial misstatements involving improper patient enrollment procedures.

Robbins LLP files class action against Nektar Therapeutics for allegedly concealing REZOLVE-AA trial protocol violations, triggering 7.77% stock decline after trial failure announcement.

Rosen Law Firm urges $NKTR investors to join class action lawsuit alleging false statements about REZOLVE-AA trial enrollment protocols caused significant shareholder losses.

Class action lawsuit filed against Nektar Therapeutics alleging executives made false statements about REZOLVE-AA trial enrollment protocols, potentially overstating trial integrity and results.

Four public companies face securities fraud class actions alleging misrepresentations in operational performance, clinical trials, and financial reporting. Lead plaintiff deadlines: May 5-8, 2026.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial integrity. Investors urged to join by May 5, 2026 deadline.

Shareholder lawsuits target Kyndryl and uniQure with lead plaintiff deadlines approaching April 2026. Investors must act quickly to join litigation.

Nektar Therapeutics faces securities lawsuit over REZOLVE-AA trial enrollment irregularities. Eligible investors have until May 5, 2026 to pursue compensation.

Class action lawsuit filed against Nektar Therapeutics alleging executives made false statements about REZOLVE-AA trial enrollment, claiming protocol violations negatively impacted results.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Shareholder lawsuits against Nektar Therapeutics ($NKTR) and Eos Energy ($EOSE) allege clinical trial and production capacity disclosure failures, with lead plaintiff deadlines in April-May 2026.

Class action lawsuit filed against Nektar Therapeutics alleging materially false statements regarding REZOLVE-AA trial enrollment protocols, claiming compromised trial integrity.